Simplify Asset Management Inc. Invests $1.57 Million in Inventiva S.A. Sponsored ADR $IVA

Simplify Asset Management Inc. acquired a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 337,662 shares of the company’s stock, valued at approximately $1,570,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its position in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after buying an additional 9,212 shares during the period. Creative Planning acquired a new position in shares of Inventiva during the second quarter worth about $32,000. NewEdge Advisors LLC acquired a new position in Inventiva during the third quarter valued at approximately $116,000. Millennium Management LLC acquired a new position in Inventiva during the third quarter valued at approximately $649,000. Finally, UBS Group AG boosted its position in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. 19.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IVA has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Truist Financial initiated coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target for the company. Barclays initiated coverage on Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price target for the company. Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, HC Wainwright set a $24.00 price target on Inventiva and gave the company a “buy” rating in a research report on Wednesday, January 28th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inventiva currently has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Performance

Shares of NASDAQ IVA opened at $5.07 on Monday. Inventiva S.A. Sponsored ADR has a 1-year low of $2.85 and a 1-year high of $7.98. The business’s 50 day moving average is $5.52 and its 200-day moving average is $5.36.

Inventiva (NASDAQ:IVA) last announced its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million during the quarter. On average, sell-side analysts forecast that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current fiscal year.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.